Senzime signs additional distribution agreements in Europe
Lena Söderström, Senzimes CEO, commented:” We are continuing our expansion in Europe and together with our distributors we are building the foundation for growth in the field of Neuromuscular monitoring”.
The TetraGraph is an innovative and user-friendly system for monitoring patients undergoing general anesthesia with muscle relaxant drugs. TetraGraph is intended to easily and precisely monitor the effects of muscle relaxant drugs and their reversal agents and to reduce postoperative complications and healthcare costs. The system consists of a portable, hand-held patient monitoring unit and non-invasive disposable sensors.
MOSS S.p.A. is focused on the promotion and distribution of advanced medical devices and high-tech equipment’s in Italy and has a vast experience in the tender business. Italy is a large country in the healthcare segment in terms of operations performed, with approximately 2.400.000 anesthesia procedures annually out of which approximately 50% are performed with muscle- relaxing drugs (www.moss-info.it).
Pharmamed represents life-saving innovations in Slovenia by internationally renowned brands of medical products in the field of Anesthesia. Slovenia’s health care equipment market is dominated by imports with a market size around USD 420 million (www.pharmamed.si/en/).
OMB LTD covering Ukraine, Moldova and Georgia, has been active in the region for 15 years with the main goal to contribute into the improvement of the health care system through the introduction of new methods into the daily practice of medical and diagnostic institutions. Every day, more than 11,000 surgical operations are carried out in Ukraine. Imports account for 90 percent of medical device sales in Ukraine (www.omb.kiev.ua/).
The distribution agreements are based on a compensation scheme of “per-unit sold” basis and are in line with current industry compensation levels without guaranteed sales.
Senzime has previously entered distribution agreements for TetraGraph in more than ten countries in Europe, as well as in Korea, Australia and New Zealand and a licensing agreement in Japan. Discussions are ongoing with distributors for additional markets and additional agreements are expected during 2018.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: email@example.com
Catrin Molund, Business Development Director
Tel: +46 708-11 69 11, firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on September 27, 2018.